Section
This article explores how CD7 CAR-T therapy leads to EBV-positive lymphoproliferative disorder by revealing CD7-negative T cell dysfunction, immunosuppressive macrophage niches, and EBV-driven B cell transformation through multi-omic techno
Autoimmune neutropenia (AiN) in adults, though rare, is a chronic condition predominantly affecting women with autoimmune comorbidities. Treatment prioritizes observation, with therapies aimed at boosting neutrophil counts or modulating imm
A large-scale analysis estimates the U.S. national burden of severe hemolytic disease of the fetus and newborn (HDFN) caused by anti-D, anti-K, and anti-c alloantibodies, revealing that severe HDFN is rare despite common alloimmunization.
Sepsis triggers mitochondrial impairment in platelets, promoting hyperactivation via ROS production. The mitochondria-specific antioxidant MitoTEMPO reverses these changes in vitro, suggesting therapeutic potential to prevent sepsis-related
This nationwide study reveals that donor cell-derived hematologic neoplasms (DDHN) after allogeneic stem cell transplantation are rare but linked mainly to inherited germline mutations in related donors, underscoring the need for comprehens
A long-term follow-up of the SPRINT trial shows no significant difference in recurrent stroke or mortality rates between initial low and moderate fixed doses of hydroxyurea in sickle cell disease, emphasizing event clustering within the fir
The phase 3 RISE UP trial demonstrates that mitapivat significantly improves hemoglobin levels in sickle cell disease, offering a novel, well-tolerated oral treatment with potential to modify disease outcomes.
A novel thrombin-cleavable FVIII-mimetic antibody enables dynamic, on-demand control of coagulation, reducing adverse thrombotic risk while maintaining efficacy in hemophilia A treatment.
This article reviews how non-alpha IL2 receptor agonist pegenzileukin can counteract CD8 T-cell exhaustion, a key mechanism in CAR T-cell (CART19) therapy failure in relapsed/refractory large B-cell lymphoma, enhancing therapeutic efficacy
Rapid and excessive expansion of ciltacabtagene autoleucel (cilta-cel) CAR T-cells associates with delayed neurotoxicity in relapsed/refractory multiple myeloma, with absolute lymphocyte count serving as a practical biomarker to guide early
This prospective nationwide study identifies baseline peripheral blood UBA1 variant allele frequency as a robust predictor of poor outcomes in VEXAS syndrome, providing a new tool for risk stratification and management.
IL-6 receptor inhibition during hematopoietic stem cell transplantation fosters type I interferon responses and promotes expansion of cytolytic CD4+ T cells, including Eomes+ subsets, augmenting antitumor immunity while mitigating graft-ver
Review of recent studies highlights venetoclax plus azacitidine as a feasible and effective therapy in younger AML patients, challenging standard intensive chemotherapy paradigms and suggesting a shift toward lower-intensity regimens with c
A multicenter Chinese registry study demonstrates that direct oral anticoagulants are noninferior to warfarin in preventing 1-year symptomatic recurrent venous thromboembolism after cerebral venous thrombosis, with exploratory bleeding outc
Targeting the mitochondrial complex I subunit NDUFS2 enhances sensitivity to FLT3 inhibitors and overcomes drug resistance in acute myeloid leukemia with FLT3-ITD mutations, suggesting a promising therapeutic strategy.
The INTERVENE trial reveals that adding midostaurin to low-dose cytarabine and venetoclax is tolerable and improves FLT3-ITD clearance and survival in older AML patients with FLT3-ITD, addressing resistance in this high-risk subgroup.
A large nationwide cohort study reveals that patients with hematological malignancies and other immunosuppressive conditions have significantly higher risks of ICU-acquired infections, while those with solid tumors do not show increased inc
This study identifies immunoglobulin heavy chain constant domain-derived peptides as promising TCR therapy targets in multiple myeloma, demonstrating selective cytotoxicity and potential to preserve humoral immunity.
Early increases in serum ST2 and REG3α within the first week after haploidentical stem cell transplantation with post-transplant cyclophosphamide predict transplant outcomes, highlighting their potential as prognostic biomarkers.
This study evaluates how treatment for cholecystitis affects the timely resumption of cancer therapy, highlighting that half of cancer patients return to therapy within six weeks, with hematologic malignancies and drainage procedures linked
